{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06191796",
            "orgStudyIdInfo": {
                "id": "XL092-009"
            },
            "organization": {
                "fullName": "Exelixis",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)",
            "officialTitle": "A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors.",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-zanzalintinib-and-zanzalintinib-nivolumab-in-participants-with-advanced-clear-cell-renal-cell-carcinoma-ccrcc-or-other-advanced-solid-tumors-stellar"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-19",
            "studyFirstSubmitQcDate": "2024-01-03",
            "studyFirstPostDateStruct": {
                "date": "2024-01-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-14",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Exelixis",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Arcus Biosciences, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to learn about the safety and preliminary antitumor activity of zanzalintinib in combination with AB521 (doublet) and in combination with AB521 plus nivolumab (triplet) in participants with advanced ccRCC or other advanced solid tumors. The main questions it aims to answer are:\n\n* The recommended doses (RDs)\n* The safety and tolerability\n* The PK and the preliminary efficacy"
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 140,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose-finding Cohort A: Zanzalintinib + AB521",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with solid tumors will receive zanzalintinib + AB521",
                    "interventionNames": [
                        "Drug: zanzalintinib",
                        "Drug: AB521"
                    ]
                },
                {
                    "label": "Dose-finding Cohort B: zanzalintinib + AB521 + nivolumab",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with ccRCC will receive zanzalintinib + AB521 + nivolumab",
                    "interventionNames": [
                        "Drug: zanzalintinib",
                        "Drug: AB521",
                        "Biological: Nivolumab"
                    ]
                },
                {
                    "label": "Expansion Cohort 1: Zanzalintinib + AB521",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with ccRCC will receive zanzalintinib + AB521",
                    "interventionNames": [
                        "Drug: zanzalintinib",
                        "Drug: AB521"
                    ]
                },
                {
                    "label": "Expansion Cohort 2: zanzalintinib + AB521 + nivolumab",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with ccRCC will receive zanzalintinib + AB521 + nivolumab",
                    "interventionNames": [
                        "Drug: zanzalintinib",
                        "Drug: AB521",
                        "Biological: Nivolumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "zanzalintinib",
                    "description": "Specified doses on specified days",
                    "armGroupLabels": [
                        "Dose-finding Cohort A: Zanzalintinib + AB521",
                        "Dose-finding Cohort B: zanzalintinib + AB521 + nivolumab",
                        "Expansion Cohort 1: Zanzalintinib + AB521",
                        "Expansion Cohort 2: zanzalintinib + AB521 + nivolumab"
                    ],
                    "otherNames": [
                        "XL092"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "AB521",
                    "description": "Specified doses on specified days",
                    "armGroupLabels": [
                        "Dose-finding Cohort A: Zanzalintinib + AB521",
                        "Dose-finding Cohort B: zanzalintinib + AB521 + nivolumab",
                        "Expansion Cohort 1: Zanzalintinib + AB521",
                        "Expansion Cohort 2: zanzalintinib + AB521 + nivolumab"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Nivolumab",
                    "description": "Specified doses on specified days",
                    "armGroupLabels": [
                        "Dose-finding Cohort B: zanzalintinib + AB521 + nivolumab",
                        "Expansion Cohort 2: zanzalintinib + AB521 + nivolumab"
                    ],
                    "otherNames": [
                        "OPDIVO\u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose-finding Stage: Number of participants with dose-limiting toxicities (DLTs)",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Expansion Stage: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the Investigator",
                    "timeFrame": "Up to 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Dose-finding Stage: Number of participants with adverse events (AEs), including serious adverse events (SAEs) and immune-mediated adverse events (imAEs)",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Dose-finding Stage: Concentration of study treatments (zanzalintinib and AB521) in plasma at specified time points",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Dose-finding Stage: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the Investigator",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Expansion Stage: Number of participants with adverse events (AEs), including serious adverse events (SAEs), and immune-mediated adverse events (imAEs)",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Expansion Stage: Duration of response (DOR) per RECIST 1.1 as assessed by the Investigator",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Expansion Stage: Progression-free survival (PFS) per RECIST 1.1 as assessed by the Investigator",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Expansion Stage: Overall survival (OS)",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Expansion Stage: Concentration of study treatments (zanzalintinib and AB521) in plasma at specified time points",
                    "timeFrame": "Up to 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Participants with unresectable advanced or metastatic disease or 1L or 2L+ clear cell Renal cell carcinoma.\n2. Have not received HIF-2\u03b1 targeted therapy previously.\n3. Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1; Eisenhauer et al, 2009) as determined by the Investigator.\n4. For all participants, archival tumor tissue material should be obtained; if archival tissue is not available or is older than 2 years, then a fresh biopsy should be obtained, if medically feasible. Specific requirements for tumor tissue samples will be described in the Laboratory Manual.\n5. Recovery to baseline or \u2264 Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.\n6. Karnofsky Performance Status (KPS) \u226570%.\n7. Screening ambulatory oxygen saturation (SpO2) \u226592%.\n8. Screening left ventricular ejection fraction (LVEF) above the institutional lower limit of normal.\n\nKey Exclusion Criteria:\n\n1. Participants who have been previously treated with a HIF-2\u03b1 targeted therapy and/or zanzalintinib.\n2. Radiation therapy for bone metastases within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Participants with clinically-relevant ongoing complications from prior radiation therapy are not eligible.\n3. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.\n4. Concomitant anticoagulation with oral anticoagulants except for 1) prophylactic use of low-dose aspirin for cardioprotection or low dose low molecular weight heparins (LMWH) or 2) therapeutic doses of LMWH or specified direct factor Xa inhibitors.\n5. Administration of a live, attenuated vaccine within 30 days prior to enrollment.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Exelixis Clinical Trials",
                    "role": "CONTACT",
                    "phone": "1-888-EXELIXIS (888-393-5494)",
                    "email": "druginfo@exelixis.com"
                },
                {
                    "name": "Backup or International",
                    "role": "CONTACT",
                    "phone": "650-837-7400"
                }
            ],
            "locations": [
                {
                    "facility": "Exelixis Site #7",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Exelixis Site #8",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90033",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Exelixis Site #9",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33176",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Exelixis Clinical Site #1",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32804",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Exelixis Site #11",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Exelixis Site #6",
                    "status": "RECRUITING",
                    "city": "Scarborough",
                    "state": "Maine",
                    "zip": "04074",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.57814,
                        "lon": -70.32172
                    }
                },
                {
                    "facility": "Exelixis Site #10",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Exelixis Site #5",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Exelixis Site #15",
                    "status": "RECRUITING",
                    "city": "Bronx",
                    "state": "New York",
                    "zip": "10469",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.84985,
                        "lon": -73.86641
                    }
                },
                {
                    "facility": "Exelixis Site #14",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10028",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Exelixis Clinical Site #3",
                    "status": "RECRUITING",
                    "city": "Port Jefferson Station",
                    "state": "New York",
                    "zip": "11776",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.92538,
                        "lon": -73.04733
                    }
                },
                {
                    "facility": "Exelixis Site #13",
                    "status": "RECRUITING",
                    "city": "Shirley",
                    "state": "New York",
                    "zip": "11987",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.80149,
                        "lon": -72.8676
                    }
                },
                {
                    "facility": "Exelixis Clinical Site #2",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Exelixis Site #4",
                    "status": "RECRUITING",
                    "city": "Spokane",
                    "state": "Washington",
                    "zip": "99208",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.65966,
                        "lon": -117.42908
                    }
                },
                {
                    "facility": "Exelixis Site #12",
                    "status": "RECRUITING",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53792",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000002292",
                    "term": "Carcinoma, Renal Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000007680",
                    "term": "Kidney Neoplasms"
                },
                {
                    "id": "D000014571",
                    "term": "Urologic Neoplasms"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5548",
                    "name": "Carcinoma, Renal Cell",
                    "asFound": "Clear Cell Renal Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M10703",
                    "name": "Kidney Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17320",
                    "name": "Urologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4906",
                    "name": "Renal Cell Carcinoma",
                    "asFound": "Renal Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1341",
                    "name": "Clear Cell Renal Cell Carcinoma",
                    "asFound": "Clear Cell Renal Cell Carcinoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077594",
                    "term": "Nivolumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1854",
                    "name": "Nivolumab",
                    "asFound": "Technique",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}